Zero Candida Applies to List its Shares on the TSX Venture Exchange

VANCOUVER, BC, Nov. 18, 2024 /CNW/ — Zero Candida Technologies Inc. (the “Company” or “Zero Candida”) (TSXV: ZCT), a technology company focused on development and commercial exploitation of a number of patents and patent applications with respect to an AI smart tampon-like device, designed to treat Candidiasis and transfer the medical information via Wi-Fi to the doctor, is pleased to announce that it has filed its application to list the Company’s common shares (the “Common Shares”) on the TSX Venture Exchange (the “TSXV”). The application is available under the Company’s profile on SEDAR+.

Zero Candida (formerly 1319743 B.C. Ltd.), has recently completed its business acquisition of Zero Candida Ltd., an Israeli private company (“ZC” and “Acquisition” respectively). In connection with the completion of the Acquisition, the Company changed its name to Zero Candida Technologies Inc. and split its share capital on a fifty-five thousand five hundred fifty five (55,555) common shares for one (1) common share basis, so that 36 common shares of the Company, without par value which were issued and outstanding immediately before completion of the Acquisition, were split into 2,000,000 common shares without par value. Pursuant to the terms of the Acquisition, the Company issued a total of 17,533,037 common shares (9.6165 common shares in the capital of the Company for each ordinary share in the capital of ZC) (the “Payment Shares”). Following completion of the Acquisition, ZC became a wholly-owned subsidiary of the Company. In addition, in connection with closing of the Acquisition, the Company issued 1,450,643 incentive stock options to employees of ZC (9.6165 incentive Options in exchange for each currently outstanding ZC Option). The terms of the exercise of the Options shall be consistent with the terms of the originally issued underlying ZC securities.

Immediately following the completion of the Acquisition, the following persons were appointed as directors of the Company:

Eli Ben-Haroosh
Asher Holzer
Orit Berger
Christina Cameron

Are you an angel?

Articles & Research.

Zero Candida Announces Launch of New Website

Company is in the Process of Being Listed on the TSX Venture Exchange (Canada) at a Proposed Valuation of 40 Million Canadian Dollars VANCOUVER, BC,…

Zero Candida Applies to List its Shares on the TSX Venture Exchange

VANCOUVER, BC, Nov. 18, 2024 /CNW/ — Zero Candida Technologies Inc. (the “Company” or “Zero Candida”) (TSXV: ZCT), a technology company focused on development and…

More than a feeling: The facts about how recurring candida affects millions of women and their quality of life

Recurrent candida or in medical terms recurrent vulvovaginal candidiasis (RVVC) is a severe and long-lasting problem for millions of women each year, causing enormous physical…